Tepotinib for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Phase 2 VISION trial showed that the MET inhibitor induced an objective response rate (ORR) of 43% among 69 treatment-naïve patients.


The median duration of response (DOR) with the agent was 10.8 months.


Among the 83 previously treated patients included in the trial, the ORR was also 43% , with a median DOR was 11.1 months.


Participants in the trial were administered oral tepotinib at a dose of 500 mg, once daily, given in 21-day cycles. 


The median duration of response was 14.0 months and the disease control rate was 72.7%.


Tumor shrinkage was reported in 89% of patients who received treatment with tepotinib.


In 11 patients who had brain metastases at baseline, outcomes with tepotinib proved to be comparable to that of the overall study population. 


Adverse effects with tepotinib included edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea. 


It can also lead to interstitial lung disease, hepatotoxicity, and embryo-fetal toxicity.


Leave a Reply

Your email address will not be published. Required fields are marked *